Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RVMD – Revolution Medicines, Inc.

Float Short %

8.6

Margin Of Safety %

Put/Call OI Ratio

0.63

EPS Next Q Diff

-0.19

EPS Last/This Y

-1.7

EPS This/Next Y

-0.48

Price

37.01

Target Price

72.4

Analyst Recom

1.06

Performance Q

-4.61

Relative Volume

0.48

Beta

1.12

Ticker: RVMD




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25RVMD37.922.130.0114113
2025-07-28RVMD37.280.660.6624161
2025-07-29RVMD36.990.660.2524201
2025-07-30RVMD37.010.650.6624363
2025-07-31RVMD37.260.650.1524396
2025-08-01RVMD36.620.570.8626626
2025-08-04RVMD37.180.570.3627325
2025-08-05RVMD38.370.551.3228053
2025-08-06RVMD36.670.550.9328075
2025-08-07RVMD34.980.550.1028351
2025-08-08RVMD35.010.560.3028211
2025-08-11RVMD34.730.556.7728416
2025-08-12RVMD35.240.574.0628607
2025-08-13RVMD36.070.562.0728567
2025-08-14RVMD36.030.560.7728705
2025-08-15RVMD36.310.561.9828775
2025-08-18RVMD36.460.651.1324891
2025-08-19RVMD36.550.656.5325066
2025-08-20RVMD36.160.651.8725114
2025-08-21RVMD36.480.650.2525173
2025-08-22RVMD37.020.635.7826072
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25RVMD37.90-38.5-223.2-4.69
2025-07-28RVMD37.33-38.5-177.0-4.69
2025-07-29RVMD37.01-38.5-188.7-4.69
2025-07-30RVMD37.01-38.5-198.1-4.69
2025-07-31RVMD37.27-38.5-207.4-4.69
2025-08-01RVMD36.63-38.5-174.3-4.69
2025-08-04RVMD37.18-38.5-218.3-4.69
2025-08-05RVMD38.39-38.5-243.0-4.69
2025-08-06RVMD36.69-38.5-137.5-4.69
2025-08-07RVMD34.95-38.5-132.9-4.69
2025-08-08RVMD35.00-31.0-91.9-4.90
2025-08-11RVMD34.72-31.0-209.0-4.90
2025-08-12RVMD35.24-47.9-246.2-5.27
2025-08-13RVMD36.07-47.9-258.9-5.27
2025-08-14RVMD36.01-47.9-219.2-5.27
2025-08-15RVMD36.33-47.9-235.7-5.27
2025-08-18RVMD36.45-47.9-227.6-5.27
2025-08-19RVMD36.54-47.9-225.8-5.29
2025-08-20RVMD36.15-47.9-205.2-5.29
2025-08-21RVMD36.48-49.0-236.0-5.28
2025-08-22RVMD37.01-49.0-244.8-5.28
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25RVMD-0.22-0.388.44
2025-07-28RVMD-0.22-5.208.44
2025-07-29RVMD-0.22-5.208.44
2025-07-30RVMD-0.22-5.208.44
2025-07-31RVMD-0.22-5.208.44
2025-08-01RVMD-0.22-5.208.44
2025-08-04RVMD-0.22-4.878.44
2025-08-05RVMD-0.22-4.878.44
2025-08-06RVMD-0.22-4.878.44
2025-08-07RVMD-0.22-4.878.44
2025-08-08RVMD-0.22-4.878.44
2025-08-11RVMD-0.22-4.868.41
2025-08-12RVMD-0.22-4.868.57
2025-08-13RVMD-0.22-4.868.57
2025-08-14RVMD-0.22-4.868.57
2025-08-15RVMD-0.22-4.868.57
2025-08-18RVMD-0.22-6.678.60
2025-08-19RVMD-0.21-6.678.60
2025-08-20RVMD-0.21-6.678.60
2025-08-21RVMD-0.21-6.678.60
2025-08-22RVMD-0.21-6.678.60
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.31

Avg. EPS Est. Current Quarter

-1.4

Avg. EPS Est. Next Quarter

-1.5

Insider Transactions

-0.21

Institutional Transactions

-6.67

Beta

1.12

Average Sales Estimate Current Quarter

22

Average Sales Estimate Next Quarter

2

Fair Value

Quality Score

7

Growth Score

21

Sentiment Score

84

Actual DrawDown %

40.7

Max Drawdown 5-Year %

-73.3

Target Price

72.4

P/E

Forward P/E

PEG

P/S

P/B

3.71

P/Free Cash Flow

EPS

-4.5

Average EPS Est. Cur. Y​

-5.28

EPS Next Y. (Est.)

-5.76

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.48

Return on Equity vs Sector %

-68.2

Return on Equity vs Industry %

-55.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.59

EBIT Estimation

-244.8
Revolution Medicines, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 700
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading